.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Chinese Patent Office
US Department of Justice
Chubb
Queensland Health
Deloitte
US Army
Healthtrust
Novartis
Accenture

Generated: June 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 064170

« Back to Dashboard
NDA 064170 describes CEFAZOLIN SODIUM, which is a drug marketed by Acs Dobfar, Facta Farma, West-ward Pharms Int, Steri Pharma, Teva Pharms, Hospira Inc, Sandoz, Glaxosmithkline, Samson Medcl, Hikma Farmaceutica, Qilu Pharm Co Ltd, Fresenius Kabi Usa, Cephazone Pharma, Abraxis Pharm, Watson Labs Inc, Bedford, and Aurobindo Pharma, and is included in thirty-one NDAs. It is available from sixteen suppliers. Additional details are available on the CEFAZOLIN SODIUM profile page.

The generic ingredient in CEFAZOLIN SODIUM is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.

Summary for NDA: 064170

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 10GM BASE/VIAL
Approval Date:Mar 18, 1998TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrengthEQ 20GM BASE/VIAL
Approval Date:Mar 18, 1998TE:RLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
McKinsey
QuintilesIMS
Moodys
Express Scripts
Mallinckrodt
Federal Trade Commission
US Department of Justice
Accenture
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot